ArticleFrontiers in immunology2026

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.

Carlos Ávila-Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.